Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency

S. Yamazaki, H. Nakamura, S. Yamagata, G. Miura, N. Hattori, K. Shinozaki, T. Sadahiro, A. Toyoda, H. Nakasa, Noritaka Ariyoshi, S. Oda, K. Harigaya, M. Kitada

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To report a case in which the serum concentration of vancomycin (VCM) reached the supratherapeutic range following oral administration in a patient with severe pseudomembranous colitis and renal insufficiency. Case summary: A 65-year-old, 70 kg weighing man with severe acute pancreatitis and acute renal failure was subjected to continuous hemodiafiltration (CHDF). CHDF could only be performed intermittently because of the unstable circulation dynamic of this patient. After admission, intravenous VCM therapy was initiated. Thereafter, oral VCM administration was begun (0.5 g every 6 h). Despite the discontinuation of intravenous VCM after the first 2 days of oral VCM, the serum VCM concentration increased gradually to 49.8 mg/l over a period of 2 weeks from the initiation of oral administration (34.4 mg/l). Based on pharmacokinetic analysis, the bioavailability of VCM was estimated to over 33%. Autopsy findings indicated broadly distributed necrosis on the lamina propria of the mucosa throughout all parts of the intestine below the duodenum. Discussion: This case indicates necessity of the careful monitoring after oral high-dose VCM administration in a patient with a broadly distributed necrosis and renal insufficiency. Conclusions: TDM should be considered according to renal function, the severity of enteritis and the total dosage of oral VCM administration.

Original languageEnglish
Pages (from-to)701-706
Number of pages6
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume47
Issue number11
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Colitis
Vancomycin
Renal Insufficiency
Oral Administration
Serum
Hemodiafiltration
Mucous Membrane
Necrosis
Pseudomembranous Enterocolitis
Enteritis
Duodenum
Acute Kidney Injury
Pancreatitis
Biological Availability
Intestines
Autopsy
Pharmacokinetics
Kidney

Keywords

  • Bioavailability
  • Pseudomembranous colitis
  • Renal insufficiency
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yamazaki, S., Nakamura, H., Yamagata, S., Miura, G., Hattori, N., Shinozaki, K., ... Kitada, M. (2009). Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. International Journal of Clinical Pharmacology and Therapeutics, 47(11), 701-706.

Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. / Yamazaki, S.; Nakamura, H.; Yamagata, S.; Miura, G.; Hattori, N.; Shinozaki, K.; Sadahiro, T.; Toyoda, A.; Nakasa, H.; Ariyoshi, Noritaka; Oda, S.; Harigaya, K.; Kitada, M.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 47, No. 11, 2009, p. 701-706.

Research output: Contribution to journalArticle

Yamazaki, S, Nakamura, H, Yamagata, S, Miura, G, Hattori, N, Shinozaki, K, Sadahiro, T, Toyoda, A, Nakasa, H, Ariyoshi, N, Oda, S, Harigaya, K & Kitada, M 2009, 'Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency', International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 11, pp. 701-706.
Yamazaki, S. ; Nakamura, H. ; Yamagata, S. ; Miura, G. ; Hattori, N. ; Shinozaki, K. ; Sadahiro, T. ; Toyoda, A. ; Nakasa, H. ; Ariyoshi, Noritaka ; Oda, S. ; Harigaya, K. ; Kitada, M. / Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. In: International Journal of Clinical Pharmacology and Therapeutics. 2009 ; Vol. 47, No. 11. pp. 701-706.
@article{d097a2495ef04e8997e146b126a4dcff,
title = "Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency",
abstract = "Objective: To report a case in which the serum concentration of vancomycin (VCM) reached the supratherapeutic range following oral administration in a patient with severe pseudomembranous colitis and renal insufficiency. Case summary: A 65-year-old, 70 kg weighing man with severe acute pancreatitis and acute renal failure was subjected to continuous hemodiafiltration (CHDF). CHDF could only be performed intermittently because of the unstable circulation dynamic of this patient. After admission, intravenous VCM therapy was initiated. Thereafter, oral VCM administration was begun (0.5 g every 6 h). Despite the discontinuation of intravenous VCM after the first 2 days of oral VCM, the serum VCM concentration increased gradually to 49.8 mg/l over a period of 2 weeks from the initiation of oral administration (34.4 mg/l). Based on pharmacokinetic analysis, the bioavailability of VCM was estimated to over 33{\%}. Autopsy findings indicated broadly distributed necrosis on the lamina propria of the mucosa throughout all parts of the intestine below the duodenum. Discussion: This case indicates necessity of the careful monitoring after oral high-dose VCM administration in a patient with a broadly distributed necrosis and renal insufficiency. Conclusions: TDM should be considered according to renal function, the severity of enteritis and the total dosage of oral VCM administration.",
keywords = "Bioavailability, Pseudomembranous colitis, Renal insufficiency, Vancomycin",
author = "S. Yamazaki and H. Nakamura and S. Yamagata and G. Miura and N. Hattori and K. Shinozaki and T. Sadahiro and A. Toyoda and H. Nakasa and Noritaka Ariyoshi and S. Oda and K. Harigaya and M. Kitada",
year = "2009",
language = "English",
volume = "47",
pages = "701--706",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "11",

}

TY - JOUR

T1 - Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency

AU - Yamazaki, S.

AU - Nakamura, H.

AU - Yamagata, S.

AU - Miura, G.

AU - Hattori, N.

AU - Shinozaki, K.

AU - Sadahiro, T.

AU - Toyoda, A.

AU - Nakasa, H.

AU - Ariyoshi, Noritaka

AU - Oda, S.

AU - Harigaya, K.

AU - Kitada, M.

PY - 2009

Y1 - 2009

N2 - Objective: To report a case in which the serum concentration of vancomycin (VCM) reached the supratherapeutic range following oral administration in a patient with severe pseudomembranous colitis and renal insufficiency. Case summary: A 65-year-old, 70 kg weighing man with severe acute pancreatitis and acute renal failure was subjected to continuous hemodiafiltration (CHDF). CHDF could only be performed intermittently because of the unstable circulation dynamic of this patient. After admission, intravenous VCM therapy was initiated. Thereafter, oral VCM administration was begun (0.5 g every 6 h). Despite the discontinuation of intravenous VCM after the first 2 days of oral VCM, the serum VCM concentration increased gradually to 49.8 mg/l over a period of 2 weeks from the initiation of oral administration (34.4 mg/l). Based on pharmacokinetic analysis, the bioavailability of VCM was estimated to over 33%. Autopsy findings indicated broadly distributed necrosis on the lamina propria of the mucosa throughout all parts of the intestine below the duodenum. Discussion: This case indicates necessity of the careful monitoring after oral high-dose VCM administration in a patient with a broadly distributed necrosis and renal insufficiency. Conclusions: TDM should be considered according to renal function, the severity of enteritis and the total dosage of oral VCM administration.

AB - Objective: To report a case in which the serum concentration of vancomycin (VCM) reached the supratherapeutic range following oral administration in a patient with severe pseudomembranous colitis and renal insufficiency. Case summary: A 65-year-old, 70 kg weighing man with severe acute pancreatitis and acute renal failure was subjected to continuous hemodiafiltration (CHDF). CHDF could only be performed intermittently because of the unstable circulation dynamic of this patient. After admission, intravenous VCM therapy was initiated. Thereafter, oral VCM administration was begun (0.5 g every 6 h). Despite the discontinuation of intravenous VCM after the first 2 days of oral VCM, the serum VCM concentration increased gradually to 49.8 mg/l over a period of 2 weeks from the initiation of oral administration (34.4 mg/l). Based on pharmacokinetic analysis, the bioavailability of VCM was estimated to over 33%. Autopsy findings indicated broadly distributed necrosis on the lamina propria of the mucosa throughout all parts of the intestine below the duodenum. Discussion: This case indicates necessity of the careful monitoring after oral high-dose VCM administration in a patient with a broadly distributed necrosis and renal insufficiency. Conclusions: TDM should be considered according to renal function, the severity of enteritis and the total dosage of oral VCM administration.

KW - Bioavailability

KW - Pseudomembranous colitis

KW - Renal insufficiency

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=70449379937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449379937&partnerID=8YFLogxK

M3 - Article

C2 - 19840535

AN - SCOPUS:70449379937

VL - 47

SP - 701

EP - 706

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 11

ER -